The Medicine & Healthcare products Regulatory Agency (MHRA) has approved the first licensed low-dose atropine (LDA) treatment for slowing the progression of childhood myopia.

This article explains the current understanding of the risk factors, diagnosis, limitations and management of glaucoma in myopes.

For the very last issue of Optometry in Practice, Professor Jonathan Jackson MCOptom reflects on the past two decades of the journal and its contribution to our learning.